During the conference, members of Azitra's management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development ...
BRANFORD, Conn., Nov. 7, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today ...
Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new investment opportunities through TipRanks' ...
BRANFORD, Conn., April 24, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, ...
Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Cofounder and Chief Operating ...
Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on ...
ATR-01, which uses a filaggrin-secreting strain of S. epidermidis, is in preclinical development for ichthyosis vulgaris Preclinical data show production of active, functional filaggrin delivered ...
Azitra Inc (NASDAQ:AZTR) shares are trading lower by 29% to $2.41 during Tuesday’s session after the company announced a mixed shelf offering of up to $50 million. The company says these securities ...
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced ...
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it has successfully screened the first patient in its Phase 1b clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results